MCKMcKesson Corporation

$1,000.62+29% 1Y

$1,000.62

$724.3752 weeks$1.0K

Is the price fair?

Fair

Neither cheap nor expensive: modest expectations priced in, but at the top of its own P/E range.

1 good, 1 to watch, 1 without data

What the price assumes~+4% a yearderived · Jun 30, 2026

Priced for ~4% a year FCF growth. The price demands less than its three-year revenue growth of 13% a year, expectations look modest.

Vs its own P/E rangedearer than 81% of its own historyderived

Expensive vs its own history: P/E 26.8 vs a 23.6 median over 31 quarters (+14% vs median).

Where this answer is blind. The growth-implied estimate assumes a fixed discount rate; capital-heavy sectors look structurally rich on it.

McKesson Corporation trades at 26.8× earnings against 27.9× for the median Healthcare name, cheaper than its own group.

26.8

Trailing P/E · Healthcare median 27.9 · cheaper than the typical name in its group

Price / sales: 0.22
Price / sales · as of 2026-Q2
Free cash flow yield: 5.5%
Free cash flow yield · Healthcare median 4.3%
Growth the price implies: +4.4%
Growth the price implies · The price pays for +4.4% free cash flow growth a year for a decade; the business has delivered +11% a year over the last three.

Details›

EV / EBIToperating margin 1.6%: the multiple describes the denominator: not meaningful
EV / salesas of 2026-Q2: 0.23
Healthcare median P/E503 names: 27.9
Free cash flow, trailing twelve months: $6.42B
Market capitalisation116.6 million shares, counted Jul 31, 2026: $116.7B
3-year revenue growth: +13%
3-year free cash flow growth: +11%

What the market has paid for these earnings: 31 quarters of its own multiple × $37.31 of trailing earnings per share
Method	Per share
Its own P/E history, lower quartile	$609.09
Its own P/E history, median	$880.79
Its own P/E history, upper quartile	$969.54
52-week range	$724.37 – $1,030.18
Today	$1,000.62

Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.